US Private Payers Could Build Evidence On Alzheimer’s Drugs With Outcomes-Based Contracts

 
• By Cathy Kelly
Alzheimer's brain money
Payers Wary Of Biomarker-Driven Approvals For High-Cost Drugs • Source: Nielsen Hobbs; the Pink Sheet | Alamy images

More from Pricing Debate

More from Market Access